NanoViricides retains consulting firm to expedite first FluCide human trials in Australia
08:51 EDT 23 Jul 2012 | Proactive Investors
NanoViricides (OTCBB:NNVC) said Monday that it has retained Australian Biologics, a regulatory affairs consulting firm, to coordinate the regulatory review and approval for the first human trials in Australia for its broad-spectrum anti-flu drug, Flu..
Original Article: NanoViricides retains consulting firm to expedite first FluCide human trials in Australia
More From BioPortfolio on "NanoViricides retains consulting firm to expedite first FluCide human trials in Australia"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
